In a recent clinical trial, an F(ab’)2 fragment targeting the sodium-dependent phosphate transport protein 2b (NaPi2b) was used in radioimmunotherapy for ovarian cancer. The gene discussed is SLC34A2; the disease is ovarian carcinoma.